Gefurulimab clinical trials
Also written ALXN1720.
How each study uses gefurulimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the gefurulimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test gefurulimab, phase 3 first.
- Dec 2026PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisPhase 3 · Alexion Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses gefurulimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisRecruitingPhase 3Alexion Pharmaceuticals, Inc.NCT06607627Written as Gefurulimab
- Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisActive, not recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT05556096Written as ALXN1720
- PK Study of Gefurulimab SC in Healthy Chinese Adult ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT06677138Written as gefurulimab
- A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT06208488Written as Gefurulimab PFS-SD
- Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With ProteinuriaCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT05314231Written as ALXN1720
- Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy SubjectsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04920370Written as ALXN1720 SC
Codes
What other systems call gefurulimab · ClinicalTrials.gg INT015308
- UNII (FDA) 6PWU78BV6CGEFURULIMABOne source FDA
- NCI Thesaurus C186389GefurulimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6PWU78BV6C | GEFURULIMAB | One source FDA |
| NCI Thesaurus | C186389 | Gefurulimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.